41 completed, 2 unknown, 1 recruiting, 1 terminated. 46 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 46 | Completed 41, Unknown 2, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Allergic Conjunctivitis: new trials by email Literature Review of Allergic Conjunctivitis trials Research Report on Allergic Conjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy REGN-2Cat, Freneslerbart, Mevonlerbart - Allergic Conjunctivitis | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 570 | 2026-07-31 | 2026-11-05 |
| Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy REGN5713, REGN5715, Placebo - Allergic Conjunctivitis | Phase 3 | Terminated | Regeneron Pharmaceuticals | 24 | 2026-01-10 | 2026-09-01 |
| A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy REGN5713, REGN5715, Placebo - Allergic Conjunctivitis | Phase 3 | Completed | Regeneron Pharmaceuticals | 54 | 2024-11-19 | 2026-04-21 |
| A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy REGN1908, REGN1909, Placebo - Allergic Conjunctivitis | Phase 3 | Completed | Regeneron Pharmaceuticals | 64 | 2024-11-06 | 2026-05-08 |
| Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 512 | 2023-04-20 | 2025-07-10 |
| Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035% - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 188 | 2022-10-12 | 2025-02-14 |
| The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 131 | 2022-01-21 | 2026-05-14 |
| Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children Bilastine, Placebo - Allergic Conjunctivitis | Phase 3 | Completed | Faes Farma, S.A. | 59 | 2021-03-26 | 2023-03-16 |
| The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis. Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 95 | 2019-12-05 | 2024-11-20 |
| A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis Dexamethasone, 0.4mg, Placebo plug with no drug - Allergic Conjunctivitis | Phase 3 | Completed | Ocular Therapeutix, Inc. | 96 | 2019-08-05 | 2021-10-07 |
| Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray Rhinocort, Budesolv, Placebo - Allergic Rhinitis, Allergic Conjunctivitis | Phase 3 | Completed | Marinomed Biotech AG | 82 | 2018-11-19 | 2020-10-12 |
| A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model. Bilastine Ophthalmic Solution 0.6%, Ketotifen Ophthalmic Solution 0.025% (Zaditen), Vehicle of Bilastine Ophthalmic Solution - Allergic Conjunctivitis | Phase 3 | Completed | Faes Farma, S.A. | 228 | 2018-04-07 | 2023-03-16 |
| A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle EM-100, Zaditor®, Vehicle - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 65 | 2018-04-07 | 2023-06-08 |
| ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 318 | 2018-03-30 | 2025-02-11 |
| A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts modified allergen extract, Placebo - Allergic Rhinitis, Allergic Conjunctivitis | Phase 3 | Unknown | Roxall Medizin | 150 | 2016-10-01 | 2015-11-03 |
| Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects Olopatadine Hydrochloride Ophthalmic Solution 0.2%, Olopatadine Hydrochloride Ophthalmic Solution 0.1%, Olopatadine 0.2% Vehicle - Allergic Conjunctivitis | Phase 3 | Completed | Alcon Research | 383 | 2014-12-01 | 2017-11-17 |
| Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis PRO-118, Olopatadine Hydrochloride - Allergic Conjunctivitis | Phase 3 | Withdrawn | Laboratorios Sophia S.A de C.V. | 2014-11-01 | 2018-10-02 | |
| A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle AC-170 0.24%, AC-170 0% - Allergic Conjunctivitis | Phase 3 | Completed | Aciex Therapeutics, Inc. | 101 | 2013-06-01 | 2017-11-09 |
| Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis AL-4943A ophthalmic solution, Olopatadine hydrochloride ophthalmic solution, 0.2%, Olopatadine hydrochloride ophthalmic solution, 0.1% - Allergic Conjunctivitis | Phase 3 | Completed | Alcon Research | 902 | 2013-01-01 | 2014-08-11 |
| A Six-Week Safety Study of an Investigational Ophthalmic Solution AL-4943A Ophthalmic Solution, AL-4943A Ophthalmic Solution Vehicle - Allergic Conjunctivitis | Phase 3 | Completed | Alcon Research | 518 | 2012-10-01 | 2014-03-27 |
Showing 20 of 46. Sign in to see all of them.
Conjunctivitis, Allergic (46) · Hypersensitivity (3) · Rhinitis, Allergic (3) · Rhinitis, Allergic, Seasonal (3) · Asthma (1) · Dermatitis, Atopic (1) · Food Hypersensitivity (1) · Nasal Obstruction (1)
Conjunctival Diseases (46) · Conjunctivitis (46) · Eye Diseases (46) · Hypersensitivity, Immediate (46) · Immune System Diseases (46) · Hypersensitivity (43) · Nose Diseases (4) · Otorhinolaryngologic Diseases (4) · Respiratory Hypersensitivity (4) · Respiratory Tract Diseases (4) · Rhinitis (4) · Airway Obstruction (1) · Bronchial Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Dermatitis (1)
Olopatadine Hydrochloride (7) · Ketotifen (6) · Ophthalmic Solutions (3) · Brimonidine Tartrate (2) · Naphazoline (2) · bepotastine besilate (2) · Budesonide (1) · Contact Lenses (1) · Dexamethasone (1) · alcaftadine (1) · bilastine (1) · bromfenac (1) · ketotifen fumarate ophthalmic solution (1)
Bausch & Lomb Incorporated (9) · Vistakon Pharmaceuticals (8) · Alcon Research (7) · Aciex Therapeutics, Inc. (4) · Regeneron Pharmaceuticals (4) · Aldeyra Therapeutics, Inc. (3) · Faes Farma, S.A. (2) · Santen Pharmaceutical Co., Ltd. (2) · Akorn, Inc. (1) · Laboratorios Sophia S.A de C.V. (1) · Marinomed Biotech AG (1) · Ocular Therapeutix, Inc. (1) · Roxall Medizin (1) · Stallergenes Greer (1) · University of Helsinki (1)
United States (27) · Canada (4) · Japan (3) · Finland (2) · Germany (2) · Austria (1) · Czechia (1) · Denmark (1) · Estonia (1) · France (1) · Latvia (1) · Lithuania (1) · Poland (1) · Slovakia (1) · Spain (1)
Brian Pall, OD, MS, FAAO (4) · Abhijit Narvekar, MS, MBBS (2) · Edward Meier, MD (2) · Ingerman Avner, MD (2) · Stacey Ackerman, MD (2) · Tim McNamara, PharmD (2) · Dawn DeCastro, MD (1) · Erkki Savilahti, Professor (1) · Eugene McLaurin, MD (1) · Eugene Protzko, MD (1) · Eva E Prieschl-Grassauer, PhD (1) · Gail L Torkildsen, MD (1) · Gail Torkildsen (1)
PMID 27466061, PMID 18595980, PMID 20488431, PMID 21250860, PMID 21771118, PMID 22093109, PMID 22991696, PMID 24517417, PMID 25163405, PMID 26266427, PMID 30326954, PMID 30472801, PMID 34857814, PMID 36811846, PMID 37438187, PMID 38105911, PMID 38687061, PMID 39328900
2016 (1), 2018 (1)